Table 1.
Comparison of clinical characteristics between the training and testing cohorts.
| Covariates | Type | Entire cohort | Testing cohort | Training cohort | P-value |
|---|---|---|---|---|---|
| Age | ≤60 | 213 (55.61 %) | 113 (59.16 %) | 100 (52.08 %) | 0.1966 |
| >60 | 170 (44.39 %) | 78 (40.84 %) | 92 (47.92 %) | ||
| Grade | G1 | 1 (0.26 %) | 0 (0 %) | 1 (0.52 %) | 0.5687 |
| G2 | 39 (10.18 %) | 19 (9.95 %) | 20 (10.42 %) | ||
| G3 | 335 (87.47 %) | 167 (87.43 %) | 168 (87.5 %) | ||
| G4 | 1 (0.26 %) | 1 (0.52 %) | 0 (0 %) | ||
| Unknown | 7 (1.83 %) | 4 (2.09 %) | 3 (1.56 %) | ||
| Stage | IIIA | 7 (1.83 %) | 5 (2.62 %) | 2 (1.04 %) | 0.2586 |
| IIIB | 16 (4.18 %) | 11 (5.76 %) | 5 (2.6 %) | ||
| IIIC | 299 (78.07 %) | 147 (76.96 %) | 152 (79.17 %) | ||
| IV | 61 (15.93 %) | 28 (14.66 %) | 33 (17.19 %) | ||
| tumor Residual | >20 mm | 72 (18.8 %) | 42 (21.99 %) | 30 (15.62 %) | 0.3589 |
| 1–10 mm | 185 (48.3 %) | 85 (44.5 %) | 100 (52.08 %) | ||
| 11–20 mm | 26 (6.79 %) | 13 (6.81 %) | 13 (6.77 %) | ||
| No macroscopic disease | 65 (16.97 %) | 33 (17.28 %) | 32 (16.67 %) | ||
| Unknown | 35 (9.14 %) | 18 (9.42 %) | 17 (8.85 %) |